Taurine improves the absorption of a fat meal in patients with cystic fibrosis.
The effect of taurine supplementation on the absorption of a fat meal was evaluated in patients with cystic fibrosis. In a cross-over design study, five patients with cystic fibrosis (12.1 +/- 2.6 years of age) and three control subjects received either placebo or taurine (30 mg/kg/d) for two 1-week periods, a month apart, followed by a fat meal test. Blood samples were drawn 0, 1, 2, 3, 5, 8 hours after the meal. Four patients with cystic fibrosis and severe steatorrhea despite appropriate enzyme therapy showed a significant (P less than .05) improvement in the absorption of triglycerides, total fatty acids, and linoleic acid while receiving taurine supplements. Three control subjects and one child with cystic fibrosis and mild steatorrhea receiving enzyme therapy did not experience such an effect. The difference in triglyceride absorption, when calculated as the area under the curve, receiving and not receiving taurine was significantly (P less than .05) correlated with the degree of steatorrhea. Furthermore, in contrast to control subjects, the fatty acid composition of chylomicrons in these four study patients showed important discrepancies with that of the fat meal and was corrected, in part, by taurine supplementation. These results suggest that taurine supplementation could be a useful adjunct in the management of patients with cystic fibrosis with ongoing fat malabsorption and essential fatty acid deficiency.
Belli
D C
DC
Department of Pediatrics, Hopital Ste-Justine, Montreal, Quebec, Canada.
Levy
E
E
Darling
P
P
Leroy
C
C
Lepage
G
G
Giguère
R
R
Roy
C C
CC
D000328:Adult; D002446:Celiac Disease / Q000188:drug therapy; D002648:Child; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000378:metabolism; D004041:Dietary Fats / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D008297:Male; D011897:Random Allocation; D013654:Taurine / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D002914:Chylomicrons; D004041:Dietary Fats; D005227:Fatty Acids; D014280:Triglycerides; D013654:Taurine; D002784:Cholesterol